福安藥業(300194.SZ):收到鹽酸昂丹司瓊片一致性評價受理通知書
格隆匯5月15日丨福安藥業(300194.SZ)公佈,公司子公司福安藥業集團寧波天衡製藥有限公司於近日收到國家藥品監督管理局下發的鹽酸昂丹司瓊片一致性評價受理通知書。
鹽酸昂丹司瓊片主要適用細胞毒性藥物化療和放射治療引起的噁心嘔吐;預防和治療手術後的噁心嘔吐。
鹽酸昂丹司瓊片申報一致性評價獲受理後,後續將進入立卷審查、技術審評及審批程序。公司將積極推進後續相關工作,如該產品最終通過一致性評價將有助於提高藥品安全性和有效性,並有助於降低臨牀應用成本,減少患者就醫費用,增加該產品市場競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.